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Abstract 
Overtreatment of early-stage low-risk prostate cancer (PC) patients represents a significant problem 
in disease management and has socio-economic implications. Development of genetic and molecular 
markers of clinically significant disease in patients diagnosed with low grade localized PC would have 
a major impact in disease management. A gene expression signature (GES) is reported for lethal PC 
in biopsy specimens obtained at the time of diagnosis from patients with Gleason 6 and Gleason 7 
tumors in a Swedish watchful waiting cohort with up to 30 years follow-up. A 98-genes GES identified 
89 and 100 percent of all death events 4 years after diagnosis in G7 and G6 patients, respectively; at 
6 years follow-up, 83 and 100 percent of all deaths events were captured. Remarkably, the 98-genes 
GES appears to perform successfully in patients’ stratification with as little as 2% of cancer cells in a 
specimen, strongly indicating that it captures a malignant field effect in prostates harboring cancer 
cells of different degrees of aggressiveness. In G6 and G7 tumors from PC patients of age 65 or 
younger, GES identified 86 percent of all death events during the entire follow-up period. In G6 and 
G7 tumors from PC patients of age 70 or younger, GES identified 90 percent of all death events 6 
years after diagnosis. Classification performance of the reported in this study 98-genes GES of lethal 
PC appeared suitable to meet design and feasibility requirements of a prospective 4 to 6 years 
clinical trial, which is essential for regulatory approval of diagnostic and prognostic tests in clinical 
setting. Prospectively validated GES of lethal PC in biopsy specimens of G6 and G7 tumors will help 
physicians to identify, at the time of diagnosis, patients who should be considered for exclusion from 
active surveillance programs and who would most likely benefit from immediate curative 
interventions.  
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Introduction 
In the United States, widespread implementation of the prostate-specific antigen (PSA) screening 
programs enabled diagnosis of more than 200,000 cases of prostate cancer each year (1). Clinically 
localized prostate cancer represents the vast majority of new cases (2). Therefore, one of the most 
significant benefits of the widespread use of PSA screening is that the prevalence of the late stage, 
advanced and high grade prostate cancer at diagnosis has declined dramatically and the vast 
majority of newly diagnosed prostate cancers are early stage and low grade tumors.  
The natural history of early stage clinically localized prostate cancer is considered favorable (2) 
and other types of cancer such as lung cancer are considered hundreds times as deadly. Despite this 
seemingly “indolent” nature, prostate cancer is the second leading cause of cancer-related deaths 
and accounts for 3.5% of all male deaths (3). Development of clear, consensus guidelines for 
physicians’ decision-making process in clinical management of early stage localized prostate cancer 
is one of the most significant public healthcare problems. Inevitable and fast approaching 
demographic changes in the Western world underscore the critical economic and logistical needs for 
a rational, evidence-based approach to the clinical management of the early stage localized prostate 
cancer. A path to solutions to this problem is complicated by a multitude of competing positions 
attempting to emphasize the perceived shortcomings and benefits of different approaches and need 
to balance multiple variables such as public health care costs, individual patients’ benefits, interests, 
socio-economic status, ethical and professional responsibilities of the medical personnel, and 
humanitarian considerations.  
Conclusive statistical evidence of the life-saving therapeutic benefits of radical prostatectomy 
versus watchful waiting in early prostate cancer have been documented in a randomized multicenter 
clinical trial: radical prostatectomy reduces disease-specific mortality, overall mortality, and the risks 
of metastasis and local progression (4-6). Immediate curative interventions are the predominant 
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therapy choice and 168,000 prostatectomies are performed each year to treat prostate cancer (7). It 
seems reasonable to conclude, that early detection of prostate cancer facilitated by PSA screening 
and aggressive use of radical prostatectomy for treatment of early prostate cancer have contributed 
to a significant extent to the reported 98-100% five-year survival rates since 1998 in the United States 
(SEER 13 areas statistics).  
However, there is a lack of consensus regarding the benefits of a population-scale PSA 
screening and a controversy about the potential for overdiagnosis and overtreatment of clinically 
insignificant disease that would not likely to become life-threatening in a man's lifetime (8). Further 
socio-economic arguments in support of significant overdiagnosis and overtreatment have been 
presented in studies indicating that prevention of one prostate cancer death would require active 
treatment of 48 men for nine years or 12 men for 14 years (9, 10). Outcome studies from 
contemporary population-based cohorts reported cumulative 10-year prostate cancer-specific 
mortality in patients with low-risk disease 2.4% and 0.7% in the surveillance group and curative intent 
groups, respectively (11), which indicates that the surveillance may be a suitable treatment option for 
majority of patients with low-risk prostate cancer. Clinical evidence that active surveillance may be a 
safe, perhaps preferred option for older men diagnosed with a very low-grade or small-volume form of 
prostate cancer were published recently by Carter and colleagues (12). Therefore, active surveillance 
with curative intent for low-risk prostate cancer is under active consideration as a potentially safe 
alternative to immediate curative intervention with the expectations that it may reduce overtreatment 
and therapy-associated adverse events. It certainly would reduce the escalating economic burden of 
cost of prostate cancer treatment. The major limitation of these studies is a short follow-up time [for 
example, in the John Hopkins study (12), the total cohort has a median follow-up of 2.7 years (range 
0.01 to 15)] which requires the use of biochemical recurrence or other “proxy” end-points for disease-
specific mortality. This limitation is particularly relevant for early prostate cancer because the overall 
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survival benefits of radical prostatectomy versus watchful waiting are not statistically apparent until 10 
years follow-up (4-6) due to the fact that a majority of death events in the watchful waiting cohorts of 
early prostate cancer occurs at or after 10 years follow-up (4-6; this study). Furthermore, significantly 
longer follow-up data are required because most patients currently diagnosed with localized prostate 
cancer are aged 60–70 years and have a life expectancy of more than 15 years (11). Most 
importantly, there are no genetic or molecular methods prospectively defining low-risk or indolent 
prostate cancer at diagnosis with sufficient specificity and selectivity to ensure the safety of patients 
and allow physicians to make informed, ethical, evidence-based disease management decision of not 
treating prostate cancer. Given the natural history of early prostate cancer and long-term survival data 
from watchful waiting cohorts, conclusive prospective validation of laboratory methods defining low-
risk indolent disease in Gleason 6 and 7 patients would require at least 10 years. Based on the 
analysis of the long-term survival data of prostate cancer patients from watchful waiting cohorts with 
up to 30 years follow-up, we reasoned that more feasible and clinically-relevant approach would be 
an attempt to identify genetic markers of lethal prostate cancer in patients with Gleason 6 and 7 
tumors which would capture a vast majority of all cancer-related death events 4-6 years after 
diagnosis. Here we report identification of gene expression signatures (GES) of lethal prostate cancer 
in biopsy specimens obtained at the time of diagnosis from patients with Gleason 6 and 7 tumors in a 
Swedish watchful waiting cohort with up to 30 years follow-up. In retrospective analysis, best-
performing GES of lethal prostate cancer identify 89% and 100% of all death events 4 years after 
diagnosis in Gleason 7 and Gleason 6 patients, respectively. GES appear to perform successfully in 
patients’ stratification with as little as 2% of cancer cells in a specimen. In Gleason 6 and 7 prostate 
cancer patients of age 65 or younger, GES identifies 86% of all death events during the follow-up. In 
Gleason 6 and 7 prostate cancer patients of age 70 or younger, GES identifies 90% of all death 
events 6 years after diagnosis. Reported in this study GES of lethal prostate cancer in biopsy 
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specimens of Gleason 6 and 7 tumors should help practicing physicians to identify at the time of 
diagnosis prostate cancer patients who should be considered for exclusion from the active 
surveillance programs and who would most likely benefit from immediate curative interventions.  
 
Materials and Methods 
Patients 
This study is based on prostate cancer patients from the population-based Swedish Watchful Waiting 
cohort of men with localized prostate cancer (4-6, 13). Distinguishing feature of this cohort is that it 
represents patients diagnosed with symptomatic early prostate cancer at the time when no PSA 
screening programs were in place: these men had symptoms of benign prostatic hyperplasia (lower 
urinary tract symptoms) and were subsequently diagnosed with prostate cancer. All men in this study 
were determined at the time of diagnosis to have clinical stage T1 and T2, Mx, and N0, according to 
the 2002 American Joint Commission Committee TNM staging system (4-6, 13). The prospective 
follow-up time in this cohort is now up to 30 years and the study cohort was followed for cancer-
specific and all cause mortality until March 1, 2006 (10). Deaths were classified as cancer-specific 
when prostate cancer was the primary cause of death as determined through a complete review of 
medical records by a study end-point committee (4-6, 13). Importantly, that in addition to the 
histopathological examination at the time of diagnosis, slides and corresponding paraffin-embedded 
formalin-fixed blocks were subsequently retrieved and re-reviewed to confirm cancer status and to 
assess Gleason scores using review, examination, and grading procedures blinded with regard to 
disease outcome (13). 
Gene expression analysis, evaluation, and selection of gene expression signatures 
Gene expression signatures (GES) were developed based on a publicly available microarray analysis 
of a Swedish Watchful Waiting cohort with up to 30 years of clinical follow up using a novel method 
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for gene expression profiling [cDNA-mediated annealing, selection, ligation, and extension (DASL) 
method] which enabled the use of formalin-fixed paraffin-embedded transurethral resection of 
prostate (TURP) samples taken at the time of the initial diagnosis. Details of the experimental 
procedure can be found in a recent publication (13) and in Gene Expression Omnibus (GEO: 
http://www.ncbi.nlm.nih.gov/geo/ ) with platform accession number: GPL5474. Full data set and 
associated clinical information is available at GEO with accession number: GSE16560. 
Feature selection was performed without assessment of differential gene expression between 
deceased and surviving patients. All 6144 genes were evaluated for association with clinical and 
pathological variables (except survival status) using correlation analysis. Different thresholds on the 
p-values (0.05; 0.01; 0.001) were used for selection of gene sets with common patterns of association 
and concordance analysis was performed using expression profiling data of snpRNA-driven cell line-
based models of prostate cancer predisposition (14, 15) to identify concordant and discordant gene 
expression signatures in cell lines and clinical samples (16-19). GES were built based on selection of 
co-regulated transcripts in various experimental conditions and clinically-relevant models, including 
prostate cancer predisposition and longevity models (14-19). Underlying concept at this stage of the 
analysis was to identify GES with concordant expression profiles across multiple data sets (16-19). 
Cox regression analysis was carried out to identify statistically significant candidate GES associated 
with patients’ survival status. Cut-off threshold of p-values was set based on the p-value of the best-
performing clinico-pathological parameter (Gleason score) in univariate Cox regression analysis (p = 
0.0113). Genes from statistically significant GES were split, combined, and permutated using random 
iteration process to find novel statistically significant combinations based on univariate Cox 
regression analysis. GES scores were derived directly from measurements of expression values of 
each gene by calculating a single numerical value for each patient. GES scores represent the 
difference between sums of expression values of genes with common co-regulation profiles which is 
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defined by up-regulation and/or positive correlation values versus down-regulation and/or negative 
correlation values. GES with p values < 0.01 were selected for further evaluation using multivariate 
Cox regression analysis of classification models which include GES and clinico-pathological co-
variats (age and Gleason score). Cut-off threshold of p-values for candidate GES selection was set 
based on the p-value of the best-performing clinico-pathological model (age and Gleason score) in 
multivariate Cox regression analysis (p = 0.0052). Candidate GES that outperformed clinico-
pathological models in multivariate Cox regression analysis were selected for further consideration 
using a split-sample validation procedure for classification threshold selection and GES classification 
performance evaluation as previously described (16-19).  
 Gene expression-based classification models were designed and evaluated through a split-
sample validation procedure which enables the unbiased estimation of the performance of a classifier 
since the evaluation is performed on an independent data set (20). Specifically, the entire data set of 
281 patients was split into training and test sets (141 and 140 patients, respectively), with 
approximately equal proportion of men with lethal and indolent prostate cancer and statistically 
undistinguishable clinical and pathological variables, e.g., age and time of diagnosis, follow up time, 
Gleason scores, percent of cancer cells in specimens (Table 1). The training set of 141 samples was 
utilized to identify and select the best classifier, whose performance was evaluated on the test set of 
140 samples without any further adjustments to the threshold selection and classification protocols 
using Kaplan-Meyer survival analysis essentially as previously described (16-19). Best-performing 
GES classifiers were further evaluated in various clinically-relevant patients’ sub-groups, including 
only Gleason 6 patients (n = 83), only Gleason 7 patients (n = 117), Gleason 6 and 7 patients (n = 
200), with further sub-division of patients in additional validation screens based on age at diagnosis 
(age 65 and younger; age 70 and younger) and percent of cancer cells in the samples (2%; 5% or 
less; 10% or less; 20% or less; 40% or less; and 50% or more). In all these secondary validation 
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screens no further adjustments to the threshold selection and classification protocols were made. 98 
genes classifier that remains statistically significant in all these validation screens is reported in this 
paper.  
Statistical significance of the Pearson correlation coefficients for individual test samples, 
clinical variables, and the appropriate reference standard were determined using GraphPad Prism 
version 4.00 software. We calculated the significance of the differences in the numbers of death 
events and surviving patients between the groups using two-sided Fisher’s exact test and the 
significance of the overlap between the lists of differentially-regulated genes using the 
hypergeometric distribution test (21). 
 
Results and discussion 
Clinical characteristics of the training and test sets are provided in Table 1, and further details for the 
entire Swedish Watchful Waiting cohort are available in a recent publication (13) and in Gene 
Expression Omnibus (GEO: http://www.ncbi.nlm.nih.gov/geo/ ) with accession number GSE16560. All 
of the 281 patients in the Swedish cohort had clinical symptoms and were diagnosed from TURP or 
adenoma enucleation samples and thus were staged depending on the proportion of the tissue that 
was cancerous either T1a or T1b (13). Analysis of survival data in the entire cohort of 281 patients 
indicates that prostate cancer patients with different Gleason scores have markedly distinct timelines 
of death events during the extended up to 30 years follow-up (Figure 1). Most striking indicator is that 
only 6% of untreated Gleason 6 prostate cancer patients died at 5 years; 14% died between 5 to 10 
years; and a majority of deaths (~ 35%) occurs 10 – 23 years after diagnosis. This analysis suggests 
that a majority of all death events (> 60%) in untreated Gleason 6 prostate cancer patients is 
occurring more than 10 years after diagnosis and during the sufficiently long follow-up period more 
than 50% of these patients will die (Figure 1). Long-term survival timelines for untreated Gleason 7 
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prostate cancer patients with symptomatic prostate cancer appear even more alarming: 27% died at 5 
years follow-up; 22% of deaths occurred between 5 to 10 years; and > 70% died during the entire 
follow-up period (Figure 1).  
Collectively, the analysis of timelines of death events in a watchful waiting cohort indicates that 
a majority of patients with symptomatic Gleason 6 and 7 prostate cancers will eventually develop 
clinically significant disease during sufficiently long follow-up period which further underscore the 
critical need to reliably define lethal prostate cancer at diagnosis. We applied the univariate Cox 
regression analysis to the entire cohort of 281 patients to identify several GES with the p value < 0.01 
which appear to perform better than the best clinico-pathological co-variate, Gleason score (p = 
0.0113; Supplemental Table S1). Most of these GES outperformed the clinico-pathological 
classification model in multivariate Cox regression analysis as well (Supplemental Table S2).  
Separating the cohort of 281 patients into training and test cohorts and using the Kaplan-Meier 
survival analysis, we identified 98 genes GES that manifest the highly significant classification 
performance in the training set, retained highly consistent classification performance in the test set, 
and remained a highly significant classifier in the pooled cohort (Figure 1). It is important to note that 
in all secondary validation screens following the training set analysis no further adjustments to the 
threshold selection and classification protocols were made.  
Notably, prostate cancer patients with identical Gleason scores (e.g., Gleason 6 patients and 
Gleason 7 patients) which were segregated into lethal and moderate disease sub-groups based on 
98 genes GES classification had highly significant differences in the survival rates (Figure 1). These 
data suggest that 98 genes GES may be useful in identifying lethal disease in patients diagnosed with 
low grade localized prostate cancer. To test this hypothesis, we performed Kaplan-Meier survival 
analysis based on 98 genes GES classification in the cohort of 200 patients with Gleason 6 and 7 
prostate cancer (Figure 2). We found that 98 genes GES is a highly significant classifier of Gleason 6 
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and 7 prostate cancer patients into sub-groups with lethal and moderate disease (Figure 2). 98 genes 
GES of lethal prostate cancer performs as a highly significant after segregation of patients into 
separate Gleason 6 and Gleason 7 sub-groups: 89% and 100% of all death events were identified 4 
years after diagnosis in Gleason 7 and Gleason 6 patients, respectively; at 6 years follow-up, 83% 
and 100% of all deaths events were captured in Gleason 7 and 6 patients, respectively (Figure 2).  
Age at diagnosis is considered among very important clinical determinants guiding the decision 
making process in clinical management of prostate cancer. This is particularly important for relatively 
younger patients because patients diagnosed with prostate cancer at age < 65 years are more likely 
to benefit from the immediate curative therapies (6). We therefore attempted to determine whether 98 
genes GES will identify lethal disease in prostate cancer patients of differing ages. Remarkably, 
Kaplan-Meier survival analysis has determined that 98 genes GES performed very efficiently in 
stratification of prostate cancer patients of 65 years or younger (Figure 3): in Gleason 6 and 7 
prostate cancer patients of age 65 or younger, GES identifies 86% of all death events during the 
follow-up. In Gleason 6 and 7 prostate cancer patients of age 70 or younger, GES identifies 90% of 
all death events 6 years after diagnosis (Figure 3).  
Proportion of cancer cells in biopsy samples is highly variable and these variations may have 
significant impact on performance of gene expression-based classifiers. In biopsy samples from the 
population-based Swedish Watchful Waiting cohort the reported percent of cancer cells in a sample 
varied dramatically from 2% to 90%. We therefore set out to determine whether the number of cancer 
cells in biopsy samples would have an impact on classification performance of the 98 genes GES of 
lethal prostate cancer. We applied the 98 genes GES classifier to prostate cancer patients which 
were segregated into distinct sub-groups based on the percent of cancer cells in a biopsy sample. 
Kaplan-Meier survival analysis demonstrates that 98 genes GES performs successfully in patients’ 
stratification regardless of the number of cancer cells in biopsy samples (Figures 4 & 5). Remarkably 
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98 genes GES appear to identify lethal disease in Gleason 6 and 7 prostate cancer patients with as 
little as 2% of cancer cells in a biopsy specimen (Figure 5). The conclusions reached based on the 
Kaplan-Meier survival analyses were confirmed using the Receiver Operating Characteristic (ROC) 
area under the curve analysis of the patients’ classification based on the 98-genes signature score in 
training (n = 141) and test (n = 140) groups (A) and different clinically-relevant sub-groups (B - D) of 
patients (Figure 6; Tables 2 & 3). Collectively, the results of the present analyses strongly indicate 
that the 98-genes GES captures a malignant field effect in the human prostates harboring cancer 
cells with markedly different clinical aggressiveness.  
The most recent beta release of web-based tools, the UCSC Xena (http://xena.ucsc.edu/ ), 
provides powerful resources to explore, analyze, and visualize the comprehensive functional cancer 
genomics datasets of thousands annotated clinical samples of the Cancer Genome Anatomy Project 
(TCGA) (https://genomecancer.soe.ucsc.edu/proj/site/xena/datapages/ ). The classification 
performance of the 98-genes GES was further validated using TCGA Prostate Cancer cohort of 550 
clinical samples with known therapy outcomes after the initial treatment (Table 4). Importantly, tumors tissues 
of the TCGA cohort comprise the prostatectomy samples which were analyzed using the state of the art 
Illumina Next Generation Sequencing technology.  
Decision making process in clinical management of low-risk localized prostate cancer is likely 
to affect life and death of thousands of patients. The problem is confounded by the fact that 
statistically significant survival benefits of curative therapy are evident only 10 years after diagnosis of 
the early-stage prostate cancer. Therefore, any genetic or molecular tests designed to aid physicians 
and patients in this process would require the regulatory approval following the successful 
prospective clinical trial. Classification performance of the reported in this study 98 genes GES of 
lethal prostate cancer appears highly suitable to meet design and feasibility requirements of the 
prospective 4 to 6 years clinical trial. Prospectively validated GES of lethal prostate cancer in biopsy 
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specimens of Gleason 6 and 7 tumors will help practicing physicians to identify at the time of 
diagnosis individual patients who should be considered for exclusion from the active surveillance 
programs and who would most likely benefit from the immediate curative interventions.  
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Table 1. Clinical characteristics of prostate cancer patients in the training and test sets 
Characteristic Training set (n = 141) Test set (n = 140) 
Years of diagnosis, range (years) 1977-1998 1977-1998 
Years of diagnosis, years (mean +/-SD) 1991 +/- 4.1 1991 +/- 4.0 
Age at diagnosis, range (years) 51-91 55-91 
Age at diagnosis, years (mean +/-SD) 74.5 +/- 7.5 73.5 +/- 7.0 
Follow-up time, range (months) 6-274 7-259 
Follow-up time, months (mean +/-SD) 102.3 +/- 57.2 101.9 +/- 55.7 
Percent of cancer in samples, range (%) 2% - 90% 2% - 90% 
Percent of cancer in samples, % (mean +/-SD) 22.9 +/- 22.7 24.0 +/- 25.5 
Gleason scores, number (%)   
Gleason 6 42 (29.8) 41 (29.3) 
Gleason 7 62 (44) 55 (39.3) 
Gleason 8-10 37 (26.2) 44 (31.4) 
Clinical outcomes, number (%)   
Deceased 105 (74.5) 101 (72.1) 
Alive 36 (25.5) 39 (27.9) 
 
Table 2. ROC area under the curve analysis of training and test data sets. 
Data sets and survival 
time 10 yrs 7 yrs 6 yrs 5 yrs 4 yrs 
Training set (n = 141) 0.85 0.854 0.814 0.788 0.794 
Test set (n = 140) 0.826 0.801 0.786 0.758 0.759 
 
Table 3. Percent of all death events at different follow-up time in lethal prostate cancer groups of 
training and test data sets. 
Data sets and survival 
time 10 yrs 7 yrs 6 yrs 5 yrs 4 yrs 
Training set (n = 141) 75% 83% 82% 84% 84% 
Test set (n = 140) 83% 88% 87% 84% 84% 
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Table 4. Classification performance of the 98-genes GES in the TCGA cohort of 550 prostate cancer 
patients with known therapy outcomes after the initial treatment.  
Categories 
Therapy outcomes after the initial treatment  
(number of patients with adverse events) 
Patients’ sub-group/ 
Adverse events Relapse Biochemical recurrence New tumors 
Poor prognosis (n = 275) 
33 44 60 
Good prognosis (n = 
275) 
10 18 20 
Patients’ sub-group/ 
Adverse events 
Therapy outcomes after the initial treatment  
 
(percent of patients with adverse events) 
Poor prognosis (top 50% 
scores) 12.00 16.00 21.82 
Good prognosis (bottom 
50% scores) 
3.64 6.55 7.27 
P value* 
0.0004 0.0006 <0.0001 
Legend: *P values were estimated using 2-talied Fisher's exact test. TCGA, the Cancer Genome Anatomy 
Project. At the date of the analyses, the median follow-up time in the prostate cancer TCGA cohort was 2.1 
years.  
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Figure legends 
Figure 1. Natural history of prostate cancer progression in patients’ population from a Swedish 
watchful waiting cohort with up to 30 years follow-up (A) and classification performance of the 98 
genes signature of lethal disease in prostate cancer patients (B-E). A, cancer-specific survival data in 
the entire watchful waiting cohort are presented to illustrate markedly distinct survival timelines of 
non-treated prostate cancer patients diagnosed with different Gleason scores prostate cancer. 
Kaplan-Meier survival analysis of the classification performance of the 98 genes GES in the training 
set (B), test set (C), and pooled cohort of 281 patients (D, E). Classification threshold 98 genes GES 
score of 270.43 units was chosen using the training set of 141 prostate cancer patients and 
consistently applied in all subsequent validation screens using the Kaplan-Meier survival analysis to 
stratify the patients into lethal disease sub-groups (score >= 270.43) and moderate/aggressive 
disease sub-group (score < 270.43). Percent value indicates the proportion of patients in the lethal 
disease sub-group. P values indicate the significance of the differences in the numbers of death 
events and surviving patients between the groups which was determined using two-sided Fisher’s 
exact test. 
 
Figure 2. Gene expression signature-based identification of lethal disease in Gleason 6 and 7 
prostate cancer patients. Kaplan-Meier survival analysis of the classification performance of the 98 
genes GES in 200 Gleason 6 and 7 prostate cancer patients (A), 83 Gleason 6 patients (B), and 117 
Gleason 7 patients (C). Classification threshold 98 genes GES score of 270.43 units was chosen 
using the training set of 141 prostate cancer patients and consistently applied in all subsequent 
validation screens using the Kaplan-Meier survival analysis to stratify the patients into lethal disease 
sub-groups (score >= 270.43) and moderate/aggressive disease sub-group (score < 270.43). Percent 
values indicate the proportion of patients in the lethal disease sub-group. P values indicate the 
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significance of the differences in the numbers of death events and surviving patients between the 
groups which was determined using two-sided Fisher’s exact test. 
 
Figure 3. Gene expression signature-based identification of lethal disease in prostate cancer patients 
with different age at diagnosis. Kaplan-Meier survival analysis of the classification performance of the 
98 genes GES in 34 prostate cancer patients of age 65 or younger (A), 64 prostate cancer patients of 
age 70 or younger (B). Bottom figures in both A and B panels show the results of Kaplan-Meier 
survival analysis for Gleason 6 and 7 patients only of corresponding age groups. Classification 
threshold 98 genes GES score of 270.43 units was chosen using the training set of 141 prostate 
cancer patients and consistently applied in all subsequent validation screens using the Kaplan-Meier 
survival analysis to stratify the patients into lethal disease sub-groups (score >= 270.43) and 
moderate/aggressive disease sub-group (score < 270.43). Percent values indicate the proportion of 
patients in the lethal disease sub-group. P values indicate the significance of the differences in the 
numbers of death events and surviving patients between the groups which was determined using 
two-sided Fisher’s exact test. 
 
Figure 4. Gene expression signature-based identification of lethal disease in prostate cancer patients 
with distinct numbers of cancer cells in biopsy samples. Kaplan-Meier survival analysis of the 
classification performance of the 98 genes GES in 59 prostate cancer patients having 2% cancer 
cells in biopsy samples (A, top), 91 patients having 5% or less cancer cells in biopsy samples (A, 
bottom), 135 patients having 10% or less cancer cells in biopsy samples (B, top), 180 patients having 
20% or less cancer cells in biopsy samples (B, bottom; and C, top), 220 patients having 40% or less 
cancer cells in biopsy samples (C, bottom). Classification threshold 98 genes GES score of 270.43 
units was chosen using the training set of 141 prostate cancer patients and consistently applied in all 
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subsequent validation screens using the Kaplan-Meier survival analysis to stratify the patients into 
lethal disease sub-groups (score >= 270.43) and moderate/aggressive disease sub-group (score < 
270.43). Percent values indicate the proportion of patients in the lethal disease sub-group. P values 
indicate the significance of the differences in the numbers of death events and surviving patients 
between the groups which was determined using two-sided Fisher’s exact test. 
 
Figure 5. Gene expression signature-based identification of lethal disease in Gleason 6 and 7 
prostate cancer patients with distinct numbers of cancer cells in biopsy samples. Kaplan-Meier 
survival analysis of the classification performance of the 98 genes GES in 52 prostate cancer patients 
having 2% cancer cells in biopsy samples (A, top), 76 patients having 5% or less cancer cells in 
biopsy samples (A, bottom), 109 patients having 10% or less cancer cells in biopsy samples (B, top), 
140 patients having 20% or less cancer cells in biopsy samples (B, bottom; and C, top), 167 patients 
having 40% or less cancer cells in biopsy samples (C, bottom). Classification threshold 98 genes 
GES score of 270.43 units was chosen using the training set of 141 prostate cancer patients and 
consistently applied in all subsequent validation screens using the Kaplan-Meier survival analysis to 
stratify the patients into lethal disease sub-groups (score >= 270.43) and moderate/aggressive 
disease sub-group (score < 270.43). Percent values indicate the proportion of patients in the lethal 
disease sub-group. P values indicate the significance of the differences in the numbers of death 
events and surviving patients between the groups which was determined using two-sided Fisher’s 
exact test. 
 
Figure 6. Receiver Operating Characteristic (ROC) area under the curve analysis of the patients’ 
classification based on the 98-genes signature score in training (n = 141) and test (n = 140) groups 
(A) and different clinically-relevant sub-groups (B - D) of patients. 
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Figure 1. 
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Figure 1. Natural history of prostate cancer progression in patients’ population from a 
Swedish watchful waiting cohort with up to 30 years follow-up and classification performance 
of the 98 genes signature of lethal disease in prostate cancer patients. 
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Figure 2. 
 
 
 26 
 
 
 
Figure 2. Gene expression signature-based identification of lethal disease in Gleason 6 and 7 
prostate cancer patients. 
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Figure 3. 
 
 
Figure 3. Gene expression signature-based identification of lethal disease in prostate cancer 
patients with different age at diagnosis. 
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Figure 4.  
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Figure 4. Gene expression signature-based identification of lethal disease in prostate cancer 
patients with distinct numbers of cancer cells in biopsy samples.  
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Figure 5. 
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Figure 5. Gene expression signature-based identification of lethal disease in Gleason 6 and 7 
prostate cancer patients with distinct numbers of cancer cells in biopsy samples.  
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Figure 6.  
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 34 
 
Figure 6 (above). Receiver Operating Characteristic (ROC) area under the curve analysis of the 
patients’ classification based on the 98-genes signature score in training (n = 141) and test (n 
= 140) groups (A) and different clinically-relevant sub-groups (B - D) of patients. 
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Supplemental Table 1. Univariate Cox regression analysis. 
   43 genes   Chi Square=   11.3649;  df=1;  p=    0.0007 
38 genes   Chi Square=   11.2901;  df=1;  p=    0.0008 
41 genes   Chi Square=   11.2790;  df=1;  p=    0.0008 
40 genes   Chi Square=   11.0182;  df=1;  p=    0.0009 
36 genes   Chi Square=   10.9231;  df=1;  p=    0.0009 
59 genes   Chi Square=    9.8677;  df=1;  p=    0.0017 
24 genes   Chi Square=    9.8116;  df=1;  p=    0.0017 
19 genes   Chi Square=    9.7022;  df=1;  p=    0.0018 
22 genes   Chi Square=    8.8170;  df=1;  p=    0.0030 
98 genes   Chi Square=    8.3266;  df=1;  p=    0.0039 
35 genes   Chi Square=    7.7065;  df=1;  p=    0.0055 
Gleason   Chi Square=    6.4196;  df=1;  p=    0.0113 
121 genes   Chi Square=    6.1059;  df=1;  p=    0.0135 
151 genes   Chi Square=    5.5270;  df=1;  p=    0.0187 
Age   Chi Square=    4.0107;  df=1;  p=    0.0452 
6144 genes   Chi Square=    3.1209;  df=1;  p=    0.0773 
   
   Coefficients, Std Errs, Signif, and Conf Intervs... 
 
   Var        Coeff.    StdErr       p       Lo95%     Hi95% 
43 genes      1       -0.0166    0.0050    0.0008   -0.0263   -0.0069 
38 genes      1       -0.0170    0.0051    0.0009   -0.0269   -0.0070 
41 genes      1       -0.0172    0.0052    0.0009   -0.0273   -0.0071 
40 genes      1       -0.0171    0.0052    0.0010   -0.0274   -0.0069 
36 genes      1       -0.0171    0.0052    0.0010   -0.0273   -0.0069 
59 genes      1       -0.0121    0.0039    0.0019   -0.0198   -0.0045 
24 genes      1       -0.0203    0.0065    0.0019   -0.0331   -0.0075 
19 genes      1       -0.0235    0.0076    0.0020   -0.0384   -0.0086 
22 genes      1       -0.0254    0.0086    0.0032   -0.0422   -0.0085 
98 genes      1       -0.0083    0.0029    0.0039   -0.0140   -0.0027 
35 genes      1       -0.0142    0.0052    0.0059   -0.0244   -0.0041 
Gleason      1       -0.1381    0.0554    0.0127   -0.2467   -0.0295 
121 genes      1       -0.0048    0.0019    0.0140   -0.0086   -0.0010 
151 genes      1       -0.0034    0.0015    0.0193   -0.0063   -0.0006 
Age      1       -0.0174    0.0086    0.0443   -0.0343   -0.0004 
6144 genes      1       -0.0002    0.0001    0.0737   -0.0004    0.0000 
   In bold GES that outperformed clinical models in multivariate Cox regression analysis 
(Supplemental Table 2). 
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Supplemental Table 2. Multivariate Cox regression analysis. 
   Clinical model 
  2 co-variates model   Chi Square=   10.5052;  df=2;  p=    0.0052 
Gleason 
     1       -0.1386    0.0553    0.0122   -0.2470   -
0.0302 
Age 
     2       -0.0176    0.0087    0.0425   -0.0347   -
0.0006 
   GES models 
  3 co-variates model   Chi Square=   17.5914;  df=3;  p=    0.0005 
 
Coefficients, Std Errs, Signif, and Conf Intervs... 
 
   Var        Coeff.    StdErr       p       Lo95%     Hi95% 
43 genes 
     1       -0.0141    0.0053    0.0081   -0.0245   -
0.0037 
Gleason 
     2       -0.0769    0.0595    0.1962   -0.1934    
0.0397 
Age 
     3       -0.0186    0.0088    0.0350   -0.0360   -
0.0013 
   2 co-variates model   Chi Square=   15.8946;  df=2;  p=    0.0004 
43 genes 
     1       -0.0168    0.0049    0.0006   -0.0264   -
0.0072 
Age 
     2       -0.0189    0.0088    0.0327   -0.0362   -
0.0016 
   2 co-variates model   Chi Square=   13.1774;  df=2;  p=    0.0014 
43 genes 
     1       -0.0138    0.0054    0.0099   -0.0243   -
0.0033 
Gleason 
     2       -0.0793    0.0594    0.1818   -0.1956    
0.0371 
   
   3 co-variates model   Chi Square=   17.3881;  df=3;  p=    0.0006 
41 genes 
     1       -0.0145    0.0056    0.0092   -0.0255   -
0.0036 
Gleason 
     2       -0.0748    0.0599    0.2119   -0.1923    
0.0426 
Age 
     3       -0.0186    0.0088    0.0351   -0.0360   -
0.0013 
   2 co-variates model   Chi Square=   15.8063;  df=2;  p=    0.0004 
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41 genes 
     1       -0.0174    0.0051    0.0006   -0.0274   -
0.0074 
Age 
     2       -0.0189    0.0089    0.0327   -0.0362   -
0.0016 
   2 co-variates model   Chi Square=   12.9783;  df=2;  p=    0.0015 
41 genes 
     1       -0.0142    0.0056    0.0111   -0.0252   -
0.0032 
Gleason 
     2       -0.0773    0.0598    0.1959   -0.1945    
0.0399 
   
   3 co-variates model   Chi Square=   17.2305;  df=3;  p=    0.0006 
40 genes 
     1       -0.0145    0.0056    0.0101   -0.0255   -
0.0035 
Gleason 
     2       -0.0755    0.0600    0.2080   -0.1930    
0.0420 
Age 
     3       -0.0188    0.0088    0.0339   -0.0361   -
0.0014 
   2 co-variates model   Chi Square=   15.6213;  df=2;  p=    0.0004 
40 genes 
     1       -0.0175    0.0052    0.0007   -0.0276   -
0.0074 
Age 
     2       -0.0190    0.0088    0.0313   -0.0364   -
0.0017 
   2 co-variates model   Chi Square=   12.7583;  df=2;  p=    0.0017 
40 genes 
     1       -0.0141    0.0057    0.0126   -0.0252   -
0.0030 
Gleason 
     2       -0.0783    0.0598    0.1906   -0.1955    
0.0390 
   
   3 co-variates model   Chi Square=   17.3697;  df=3;  p=    0.0006 
38 genes 
     1       -0.0144    0.0055    0.0092   -0.0252   -
0.0036 
Gleason 
     2       -0.0735    0.0601    0.2213   -0.1912    
0.0443 
Age 
     3       -0.0187    0.0088    0.0344   -0.0361   -
0.0014 
   2 co-variates model   Chi Square=   15.8509;  df=2;  p=    0.0004 
38 genes      1       -0.0172    0.0050    0.0006   -0.0271   -
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0.0074 
Age 
     2       -0.0190    0.0089    0.0321   -0.0363   -
0.0016 
   2 co-variates model   Chi Square=   12.9222;  df=2;  p=    0.0016 
38 genes 
     1       -0.0141    0.0056    0.0114   -0.0250   -
0.0032 
Gleason 
     2       -0.0760    0.0600    0.2050   -0.1935    
0.0415 
   
   3 co-variates model   Chi Square=   17.0730;  df=3;  p=    0.0007 
36 genes 
     1       -0.0145    0.0057    0.0108   -0.0256   -
0.0033 
Gleason 
     2       -0.0736    0.0603    0.2219   -0.1918    
0.0445 
Age 
     3       -0.0188    0.0088    0.0332   -0.0362   -
0.0015 
   2 co-variates model   Chi Square=   15.5583;  df=2;  p=    0.0004 
36 genes 
     1       -0.0174    0.0052    0.0007   -0.0275   -
0.0073 
Age 
     2       -0.0191    0.0088    0.0307   -0.0365   -
0.0018 
   2 co-variates model   Chi Square=   12.5661;  df=2;  p=    0.0019 
36 genes 
     1       -0.0141    0.0057    0.0138   -0.0253   -
0.0029 
Gleason 
     2       -0.0765    0.0602    0.2035   -0.1945    
0.0414 
   
   3 co-variates model   Chi Square=   14.8255;  df=3;  p=    0.0020 
 
Coefficients, Std Errs, Signif, and Conf Intervs... 
 
   Var        Coeff.    StdErr       p       Lo95%     Hi95% 
98 genes 
     1       -0.0064    0.0031    0.0379   -0.0125   -
0.0004 
Gleason 
     2       -0.0918    0.0593    0.1219   -0.2081    
0.0245 
Age 
     3       -0.0177    0.0088    0.0432   -0.0349   -
0.0005 
   2 co-variates model   Chi Square=   12.3870;  df=2;  p=    0.0020 
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98 genes 
     1       -0.0083    0.0029    0.0037   -0.0139   -
0.0027 
Age 
     2       -0.0177    0.0087    0.0430   -0.0349   -
0.0006 
   2 co-variates model   Chi Square=   10.7698;  df=2;  p=    0.0046 
98 genes 
     1       -0.0065    0.0031    0.0374   -0.0126   -
0.0004 
Gleason 
     2       -0.0918    0.0593    0.1216   -0.2081    
0.0244 
   
   3 co-variates model   Chi Square=   16.1992;  df=3;  p=    0.0010 
 
Coefficients, Std Errs, Signif, and Conf Intervs... 
 
   Var        Coeff.    StdErr       p       Lo95%     Hi95% 
22 genes 
     1       -0.0219    0.0092    0.0174   -0.0400   -
0.0039 
Gleason 
     2       -0.0855    0.0593    0.1493   -0.2016    
0.0307 
Age 
     3       -0.0198    0.0088    0.0251   -0.0371   -
0.0025 
   2 co-variates model   Chi Square=   14.0843;  df=2;  p=    0.0009 
22 genes 
     1       -0.0270    0.0085    0.0016   -0.0437   -
0.0103 
Age 
     2       -0.0203    0.0088    0.0213   -0.0377   -
0.0030 
   2 co-variates model   Chi Square=   11.2099;  df=2;  p=    0.0037 
22 genes 
     1       -0.0201    0.0092    0.0294   -0.0382   -
0.0020 
Gleason 
     2       -0.0907    0.0592    0.1253   -0.2066    
0.0253 
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Supplemental Table 3. Potential clinical utility of the gene expression signatures in management of 
active surveillance programs of prostate cancer patients with Gleason 6 and 7 tumors.  
Gene expression 
signature 
Gleason sum score of 
eligible patients 
Expected percent of 
patients’ population 
Potential clinical utility in management 
of active surveillance programs 
45 genes (G7) Gleason sum 7 18% Identification of patients with high 
likelihood of clinically fatal disease 
(median survival 44 months; 19% 
survival after 5 yrs; 100% fatality at 10 
yrs) 
121 genes (G7) Gleason sum 7 35% Identification of patients with high 
likelihood of clinically lethal disease 
(median survival 67 months; 39% 
survival after 6 yrs; 90% fatality at 15 
yrs) 
16 genes (G7) Gleason sum 7 29% Identification of patients with high 
likelihood of clinically lethal disease 
(median survival 77 months; 56% 
survival after 5 yrs; 94% fatality at 15 
yrs) 
18 genes (G7) Gleason sum 7 50% Identification of patients with high 
likelihood of clinically lethal disease 
(median survival 76 months; 49% 
survival after 6 yrs; 22% survival after 
10 yrs; 93% fatality at 15 yrs) 
58 genes (G6) Gleason sum 6 31% Identification of patients with high 
likelihood of clinically aggressive 
disease (median survival 150 months; 
56% survival after 10 yrs; 84% fatality 
at 15 yrs) 
21 genes (G6) Gleason sum 6 18% Identification of patients with high 
likelihood of clinically indolent disease 
(93% survival after 10 yrs; 13.3% 
cumulative fatality) 
18 genes (G6) Gleason sum 6 63% Identification of patients with high 
likelihood of clinically aggressive 
disease (median survival 159 months; 
94% survival after 5 yrs; 33% fatality 
after 10 yrs; 36% survival after 15 yrs) 
121 genes (G8) Gleason sum 8-10 57% Identification of patients with high 
likelihood of clinically fatal disease 
(median survival 44 months; 77% 
fatality after 5 yrs; 11% survival after 6 
yrs; 100% fatality at 13 yrs) 
Legend: Gene expression signatures were developed based on a publicly available microarray analysis of a 
Swedish Watchful Waiting cohort with up to 30 years of clinical follow up using a novel method for gene 
expression profiling [cDNA-mediated annealing, selection, ligation, and extension (DASL) method] which 
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enabled the use of formalin-fixed paraffin-embedded transurethral resection of prostate (TURP) samples taken 
at the time of the initial diagnosis. Details of the experimental procedure can be found in a recent publication 
(Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami HO, Fall K, Mucci LA, 
Kantoff PW, Stampfer M, Andersson SO, Varenhorst E, Johansson JE, Gerstein MB, Golub TR, Rubin MA, 
Andrén O. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med 
Genomics. 2010 3:8. PMID: 20233430; PMCID: PMC2855514) and in Gene Expression Omnibus (GEO: 
http://www.ncbi.nlm.nih.gov/geo/ ) with platform accession number: GPL5474. Full data set and associated 
clinical information is available at GEO with accession number: GSE16560.  
 
 
 
